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Abstract:  Problem statement: Adiponectin is a hormone expressed from adipose tissue in people, 
rodents and dogs. Adiponectin has anti-inflammatory action with beneficial effects on cardiovascular 
health  and  insulin  sensitivity.  With  increasing  fat  mass,  adiponectin  concentrations  paradoxically 
decrease.  Adiponectin’s  role  in  metabolism  and  diabetes  mellitus  is  of  interest  in  feline  medicine 
because cats are susceptible to developing type II diabetes with weight gain. This study determined 
relative amounts of adiponectin mRNA expression from various body tissues and organs in domestic 
cats. Approach: Two intact male cats and one intact female cat were evaluated post-mortem. All cats 
were  estimated  to  be  young  adults  and  had  lean  body  conditions.  Tissues  samples  from  inguinal 
subcutaneous  adipose,  visceral  mesenteric  adipose,  liver,  skeletal  muscle,  cardiac  muscle,  aorta, 
stomach fundus, duodenum, pancreas, thyroid gland, adrenal gland (cortex and medulla) and renal 
cortex were collected and frozen. Following RNA extraction, adiponectin mRNA expression of each 
tissue was detected using Reverse Transcriptase (RT) real-time (Q) PCR. Results: Visceral adipose 
tissue had the highest level of expression, averaging 12% higher than subcutaneous adipose. All other 
tissues had negligible levels of expression compared to adipose samples.  Conclusion: This study 
provided a valuable step for adiponectin research in cats by determining which tissues express this 
hormone.  Cats  differ  from  human  beings  by  expressing  higher  levels  of  adiponectin  in  visceral 
compared to subcutaneous  fat. The  metabolic impact of this expression pattern is not known and 
provides a basis for future research. 
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INTRODUCTION 
 
  The metabolic role of adipose tissue is a rapidly 
expanding area of research. Discovery of cell-signaling 
proteins  secreted  by  adipocytes,  termed  adipokines, 
dispelled  the  belief  that  fat  is  a  passive  tissue 
functioning  solely  for  energy  storage  and  insulation. 
Adiponectin is the most abundantly secreted adipokine 
with serum concentrations in the µg mL
-1 range, which 
is  three  orders  of  magnitude  higher  than  leptin 
(Whitehead  et  al.,  2006).  One  of  the  most  intriguing 
aspects  of  adiponectin  is  its  paradoxical  decline  with 
increases  in  body  fat  mass.  Adiponectin  is  closely 
associated  with  insulin  sensitivity  and  has  beneficial 
cardiovascular effects (Matsuzawa, 2005; Weyer et al., 
2001;  Trujillo  and  Scherer,  2005;  Kern  et  al.,  2003; 
Hara et al., 2006; Tarquini et al., 2007). Adiponectin’s 
role in metabolism and diabetes mellitus is of interest in 
feline  medicine  because  cats  are  susceptible  to 
developing  insulin  resistance  and  Type-2  diabetes  in 
response to weight gain (Appleton et al., 2001). Only 
one study has evaluated the mRNA expression of feline 
adiponectin and it was limited in the scope of tissues 
examined (Hoenig et al., 2007; Zini et al., 2009). 
  Although  adiponectin  is  secreted  predominately 
from adipocytes in the species studied, small amounts 
have been found in preadipocytes from bone marrow 
(Yokota  et  al.,  2002),
  cultured  cardiac  myocytes  and 
portal   endothelial cells (Kaser et al., 2005). In dogs, 
adiponectin mRNA expression has only been detected 
in  adipose  tissue  (Ishioka  et  al.,  2006).    In  a  single 
study of cats, adiponectin expression was examined in 
adipose tissue and skeletal muscle (Hoenig et al., 2007; 
Zini et al., 2009). Visceral adipose appeared to have 
higher  tissue  expression  of  adiponectin  than 
subcutaneous  adipose  tissue.  This  is  in  contrast  to 
studies  in  human  beings  where  subcutaneous  adipose 
tissue secretes 25-60% more adiponectin than visceral American J. Animal & Vet. Sci., 5 (4): 228-232, 2010 
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adipose  (Hernandez-Morante  et al., 2007; Lihn et al., 
2004;  Fisher  et  al.,  2002;  2005).  Findings  in  human 
beings coincide with research linking visceral adiposity 
to  lower  levels  of  circulating  adiponectin  and  higher 
risks of cardiovascular disease and T2DM (Ryo et al., 
2004; Hanley et al., 2007). 
  To fully understand adiponectin’s impact on feline 
metabolism,  it  is  important  to  determine  the  tissues 
from  which  it  is  derived.  It  is  not  uncommon  for 
hormones  and  adipokines  to  have  dramatic  species 
differences  in  their  secretion  patterns.  For  example, 
resistin is a hormone secreted almost exclusively from 
adipose tissue in rodents, but it is predominately found 
in bone and lung tissues of human beings (Steppan and 
Lazar, 2004; Patel et al., 203). The goal of this study 
was  to  quantify  adiponectin’s  expression  in  various 
tissues and determine the primary areas of adiponectin 
production. By knowing which tissues exert the greatest 
influence  on  circulating  adiponectin,  we  may  better 
understand  which  areas  of  the  body  impact  insulin 
sensitivity. As a result, new preventive and therapeutic 
measures may be implemented to increase circulating 
adiponectin  levels  and  subsequently  improve  insulin 
sensitivity in cats. 
 
MATERIALS AND METHODS 
 
Sample  collection:  Three  feline  cadavers  were 
obtained  from  a  local  humane  society.  Cats  were 
euthanized  for  reasons  unrelated  to  the  study  and 
samples  were  collected  immediately  after  expiration. 
The cats’ physical parameters are described in Table 1. 
The  following  tissues  were  harvested  using  sterilized 
instruments  treated  to  remove  DNA  contamination: 
(DNA Away, Molecular Bioproducts, San Diego, CA) 
inguinal  subcutaneous  adipose,  visceral  mesenteric 
adipose, liver from the left lateral lobe, skeletal muscle 
from the gastrocnemius, left ventricular cardiac muscle, 
aorta,  stomach  fundus,  duodenum,  pancreas,  thyroid 
gland,  adrenal  gland  (cortex  and  medulla)  and  renal 
cortex. Care was taken to remove surrounding fat from 
tissues  and  new  instruments  were  used  for  the 
collection  of  each  sample.  Tissues  were  immediately 
placed  in  a  RNA  preservative  (RNAlater,  Qiagen, 
Valencia, CA) and frozen to -80°C.  
 
Table 1: Description of sample cats 
        Body  Body 
    Age    weight  condition 
  Sex  (years)  Breed  (kg)  score  
Cat A  Female  <3  Domestic short hair  3.14  4/9 
Cat B  Male  1-2  Domestic short hair  4.45  5/9 
Cat C  Male  1-2  Domestic short hair  3.96  5/9 
Note: Description of cats from which tissue samples were collected 
RNA  extraction  and  PCR:  Messenger  RNA  was 
extracted  from  adipose  tissue  using  a  lipid-specific 
extraction  kit  to  improve  RNA  yield  (RNeasy  lipid 
tissue mini kit, Qiagen, Valencia, CA). All other tissues 
were extracted using a standard mRNA extraction kit 
(RNeasy  minikit,  Qiagen,  Valencia,  CA).  On-column 
DNase digestions were performed during the extraction 
(RNase-free  DNase  set,  Qiagen,  Valencia,  CA)  and 
samples   were   stored   at -80°C.  An additional DNase 
treatment  was  performed  to  remove  residual  DNA 
before  samples  were  reverse  transcribed  (TURBO 
DNA-free, Ambion, Austin, TX). 
  Reverse-Transcription (RT) was performed on 
each sample according to the SuperScript
TM II Reverse 
Transcriptase  manufacturer  protocol  (Superscript  II 
Reverse Transcriptase, Invitrogen, Carlsbad, CA). The 
reverse  priming  and  quantitative,  real-time  (Q)  PCR 
were performed with the following primers and FAM-
labeled probe designed for this study (Taqman custom 
gene  expression  assay,  Applied  Biosystems,  Foster 
City, CA). They included forward primer (18 µM): 184 
-CCGGGTGAAAAGGGTGAG-201,  probe  (5  µM): 
222-AACAAGACCTGGATCTCCT-204  and  reverse 
primer  (18  µM):  245-
TCACCAGTGTCACCCTTAGGA-225.  cDNA 
sequence  locations  correspond  to  GenBank  accession 
number  AB115956.  FAM-labeled  probes  are  more 
specific than cyber green markers used previously for 
feline  adiponectin  PCR  and  the  specificity  of  the 
primers  and  probe  were  confirmed  through  DNA 
sequencing of the PCR product (Zini et al., 2009). For 
Q-PCR, cDNA (2 µL) was combined with the primer 
and  probe  mixture  (1  µL),  (Taqman  custom  gene 
expression assay, Applied Biosystems, Foster City, CA) 
Taq  polymerase  (2x  concentration,  10  µL),  (Taqman 
Universal PCR master mix, Applied Biosystems, Foster 
City, CA) and water (7 µL). The total reaction volume 
was 20 µL. The amplification profile consisted of 2 min 
at 50°C and 10 min at 95°C, followed by 40 cycles of 
95°C for 15 sec and 60°C for 1 min. The ubiquitously 
expressed  housekeeping  gene,  Glyceraldehyde-3-
Phosphate  Dehydrogenase  (GAPDH)  was  used  as  a 
control  to  assess  the  relative  quantity  of 
mRNAextracted from different tissues. RT and Q-PCR 
using the same protocol as above with GAPDH specific 
primers and probes  were performed  for each sample. 
Extracted  mRNA  from  tissue  samples  that  had  not 
undergone an RT reaction was also subjected to Q-PCR 
using the adiponectin primers to assess potential DNA 
contamination in the samples. 
 
Statistical methods: To confirm linearity of each Q-
PCR assay performed, a standard curve of adiponectin American J. Animal & Vet. Sci., 5 (4): 228-232, 2010 
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DNA  using  ten  fold  dilutions  ranging  from  1´10
1  to 
1´10
5 was measured. To obtain a consistent number of 
adiponectin DNA copies, a plasmid with an adiponectin 
gene insert was constructed (TA cloning kit (pCR 2.1), 
Invitrogen,  Carlsbad,  CA).  Standard  curve  equations 
were developed using SPSS v. 15 (SPSS v. 15, SPSS 
Inc., Chicago, IL).   
 
RESULTS 
 
  The  efficiency  of  RNA  tissue  extraction  using 
GAPDH showed all tissues had Q-PCR CT values well 
below  comparable  adiponectin  levels.  Mean  GAPDH 
and  adiponectin  CT  values  for  all  tissues  were  14.9 
(±3.8)  and  25.4  (±6.3),  respectively.  The  amount  of 
DNA  remaining  in  tissues  was  measured  using 
untranscribed  mRNA  in  the  Q-PCR  reaction.  Cats  A 
and C had no detectable DNA contamination. Cat B had 
small  amounts  of  DNA  detected  in  the  pancreas  and 
adrenal  gland.  Adiponectin  levels  measured  in  these 
two tissues were negligible compared to adipose tissue; 
therefore, the DNA contamination did not affect overall 
results. To compare adiponectin expression of various 
tissues, the number of DNA copies of the adiponectin-
inserted plasmid was calculated (9.89´0
19 mL
-1). The 
standard curves created from the diluted plasmid DNA 
fit a logarithmic curve (R
2>0.97) and the CT values from 
the various tissues were then fit to the curves. Once the 
PCR values were standardized to the curve, the relative 
number of DNA copies of each tissue was compared to 
visceral  adipose  tissue  (Table  2).  Expression  of 
adiponectin  was  highest  in  visceral  adipose  tissue  in 
cats A and C and equal to subcutaneous adipose in cat 
B.  Both  types  of  adipose  tissue  had  high  levels  of 
adiponectin expression compared to other  tissue  types.  
 
Table 2: Relative amounts of adiponectin mRNA expression 
Tissue type  Cat A  Cat B  Cat C  Mean 
Renal cortex  <0.1  <0.1  <0.1  <0.1 
Skeletal muscle  0.3  <0.1  <0.1  0.1 
Liver  <0.1  <0.1  <0.1  <0.1 
Thyroid gland  <0.1  0.1  1.1  0.4 
Aorta  <0.1  0.7  2.4  1.0 
Fundus  0.2  <0.1  0.6  0.3 
Cardiac muscle  <0.1  <0.1  0.3  0.1 
Adrenal gland  <0.1  0.1  6.5  2.2 
Duodenum  <0.1  <0.1  0.1  <0.1 
Pancreas  <0.1  0.3  0.3  0.2 
Subcutaneous adipose  87.0  100.0  75.0  87.3 
Visceral adipose  100.0  100.0  100.0  100.0 
Note:  The  expression  of  adiponectin  mRNA  relative  to  visceral 
adipose. Note the high levels of expression in the aortic and adrenal 
tissue  from  Cat  C.  This  is  most  likely  due  to  contamination  with 
adipocytes given the small amounts detected in the other 2 cats 
With  the  exception  of  subcutaneous  adipose,  adrenal 
tissue and aorta, adiponectin expression was less than 
1%  of  visceral  adipose  in  all  samples.  Expression  of 
adiponectin in all tissues was less than 3% of adipose 
tissue expression.  
 
DISCUSSION 
 
  Based on a prevalence rate of 0.0124%, there are 
over one hundred thousand diabetic cats in the United 
States (Prahl et al., 2007). This number is expected to 
rise as the rate of feline obesity increases. Therefore, 
researchers and veterinarians need to look for new ways 
to  combat  and  treat  feline  obesity  and  diabetes. 
Adiponectin  is  an  attractive  target  for  early  diabetic 
screening and new drug therapies and understanding its 
physiology  is  critical  for  therapeutic  applications  in 
felids. The twelve types of tissue sampled for this study 
were  chosen  either  for  their  involvement  in 
carbohydrate and lipid metabolism or for their known 
endocrine  functions.  Although  adipose  and  skeletal 
muscle  had been previously evaluated in  the cat,  many 
other tissues hold the potential to secrete adiponectin. As 
stated previously, small amounts of adiponectin expression 
have  been  detected  in  several  human  and  rodent  tissue 
types  and  adipokines  can  have  dramatic  species 
differences in their secretion patterns (Yokota et al., 2002; 
Kaser et al., 2005; Steppan and Lazar, 2004; Patel et al., 
2003;  Berner  et  al.,  2004).  Our  results  show  that 
adiponectin is secreted almost exclusively from adipose 
tissue  in  the  cat.  In  comparison  to  visceral  adipose, 
most other tissues had expression values of less than 
one percent. The aorta and adrenal gland tissue from cat 
C had expression levels of 2.4 and 6.5%, respectively. 
Cats A and B had levels below 1% for these tissues. 
Despite efforts to minimize contamination of samples 
by adipose tissue, the adrenal and aorta samples from 
cat C may have been contaminated by surrounding fat 
and  this  would  falsely  increase  adiponectin  mRNA 
levels. Although we cannot rule out the possibility that 
aortic  and  adrenal  tissues  secrete  small  amounts  of 
adiponectin,  the  amounts  of  adiponectin  mRNA 
detected in the non-fat samples are considered clinically 
and biologically irrelevant and are probably the result 
of adipocyte contamination within the tissues. 
  Identifying the tissues that secrete adiponectin in 
cats  is  an  important  first  step  in  characterizing  this 
hormone. This  study demonstrates cats are similar to 
other  species  in  that  adiponectin  is  secreted  almost 
exclusively  from  adipose  tissue.  However,  cats  differ 
from  other  species  in  their  relative  expression  of 
adiponectin  from  visceral  and  subcutaneous  adipose. 
We  found  visceral  adipose  samples  express American J. Animal & Vet. Sci., 5 (4): 228-232, 2010 
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approximately  12%  more  adiponectin  mRNA  than 
subcutaneous samples. The finding that visceral adipose 
expresses more adiponectin mRNA than subcutaneous 
adipose is in agreement with another study in cats in 
which  visceral  adipose  expressed  50%  more 
adiponectin  than  subcutaneous  adipose  (Zini  et  al., 
2009).  This  is  an  intriguing  finding  because  humans 
secrete  25-60%  less  adiponectin  from  visceral  fat 
(Hernandez-Morante  et  al.,  2007;  Lihn  et  al.,  2004; 
Fisher  et  al.,  2002).  Since  humans  secrete  more 
adiponectin from subcutaneous adipose, a person with 
more  visceral  fat  will  have  less  adiponectin  than  a 
person with the same body fat content who has more fat 
distributed  subcutaneously.  This  is  a  possible 
mechanism  for  the  deleterious  cardiovascular  and 
metabolic affects associated with visceral adiposity in 
people  (Bergman  et  al.,  2007).  The  opposite  pattern 
may  be  seen  in  cats.  A  cat  with  larger  deposits  of 
visceral fat would be expected to have more circulating 
adiponectin than a cat of the same body fat mass with 
more  subcutaneous  adipose  tissue.  Perhaps  visceral 
adiposity may not be as detrimental to cats as it is in 
humans and maybe subcutaneous adipose depots may 
contribute  more  to  the  development  of  insulin 
resistance and diabetes in cats.  
  The results of this study are intriguing and provide 
the opportunity for many additional projects. It would 
be  interesting  to  compare  adiponectin  expression 
patterns in adipose tissue of cats with different genders, 
ages, breed and body condition scores.  For example, 
could  adiponectin  expression  hold  the  key  to 
understanding  the  increased  incidence  of  diabetes 
mellitus  in  male  cats  (Prahl  et  al.,  2007).  From  the 
results  of  this  study,  it  appears  adiponectin  is  an 
adipokine  expressed  only  from  fat  tissue  in  cats  and 
future research efforts can concentrate on how adiposity 
patterns  influence  adiponectin  and  if  this  relationship 
impacts insulin sensitivity. 
 
CONCLUSION 
 
  The results of this study demonstrate adiponectin is 
expressed  from  only  adipose  tissue  in  cats.  Unlike 
humans, cats appear to have more mRNA expression 
from visceral compared to adipose tissue.  
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